Formally known as KarXT, xanomeline-trospium chloride (Cobenfy) receives approval from the FDA for the treatment of schizophrenia in adults. The FDA approved xanomeline and trospium chloride (Cobenfy) capsules, the first antipsychotic medication for schizophrenia that targets cholinergic receptors instead of the traditional dopamine receptors, for adults with schizophrenia.1 The therapy, developed by Bristol Myers-Squibb, offers a new treatment option for patients affected by the debilitating mental condition, and is the first new drug approved for schizophrenia in decades.